Compare NVEC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | CLLS |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.2M | 384.3M |
| IPO Year | 1995 | 2014 |
| Metric | NVEC | CLLS |
|---|---|---|
| Price | $68.33 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 21.7K | ★ 43.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | ★ $25,874,694.00 | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.50 | $1.10 |
| 52 Week High | $82.30 | $5.48 |
| Indicator | NVEC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 40.77 |
| Support Level | $63.56 | $3.41 |
| Resistance Level | $74.14 | $3.77 |
| Average True Range (ATR) | 2.59 | 0.19 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 46.02 | 13.54 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.